Corporate naming is taking over. Welcome to Toronto, brought to you by Rogers
This satirizes our often ridiculous tendency to sell naming rights. But in a fragmented narrative that jumps back and forth chronologically, it also serves as an intentional point of confusion. As a reader, you have to work out and keep track of which years come in which order.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause
Sarepta Therapeutics' (SRPT) stock has been hammered in the past week after the company was forced to pause shipments of its top-selling Duchenne muscular dystrophy (DMD) therapy Elevidys — throwing the future of the company into question. Elevidys netted $821 million of the company's $1.78 billion in 2024 revenue and contributed to more than 50% of the company's $513 million in second quarter revenue this year. It's the company's top-selling product. It's why seven analysts have downgraded the stock since Friday, including Bank of America's Tazeen Ahmad on Wednesday. Ahmad downgraded the stock to Underperform and revised the firm's price target to $10 from $20. The stock is currently trading at $13.90 per share and closed down more than 2% on Wednesday. Sarepta "has requested a meeting with FDA and might have more visibility on length of the pause once FDA responds to their submission for a revised label," Ahmad wrote in a note to clients. "In short, we think this could impact the Elevidys brand further, limiting uptake following highly focused media attention as well as a renewed chance of Elevidys being removed from the US market." Leerink Partners downgraded the stock last week from Outperform to Market Perform. Analyst Joseph Schwartz wrote in a note to clients on Monday that how long the pause lasts is important for future modeling. "This decision is also roughly aligned with our published SRPT model, which assumes a significant slowing of sales in the third quarter, zero sales in the fourth quarter, and a resumption of shipments in early 2026," Schwartz wrote. "We lack visibility into how long this pause may last, or what the intermediate scenarios are from here (e.g., a narrower approval)." The stock now has five Buy, 17 Hold, and four Sell ratings. Domino effect The technology to deliver the therapy in Elevidys is at the center of the issue facing the company. A 51-year-old, late-stage patient in a phase 1 trial of a different muscular dystrophy therapy, known only by its trial name, SRP-9004, died from liver toxicity last month, but Sarepta failed to disclose the death — even as it announced it was discontinuing the trial as part of a restructuring last week. That began the domino effect of downgrades and the stock sell-off as analysts questioned why the company had kept quiet. On a call with investors Friday, CEO Doug Ingram defended his reasoning for not mentioning it. "We did not discuss this matter in our call on Wednesday because it was neither material nor central to the topics at hand on Wednesday," Ingram said. In a note following the call, Leerink's Schwartz wrote, "Is This Material?!? All Credibility Lost." It's the third death linked to a gene therapy from the company this year and a reason why the FDA previously required the company to add new warning labels to Elevidys, which is part of the pause in shipments currently. But now, the company's future is in flux as its revenue stream has been paused for an undetermined amount of time. Jefferies analyst Andrew Tsai, one of the few who has maintained a Buy rating, said the company could defend the therapy as sicker and older patients have been more negatively impacted, while younger patients who are still able to move independently have benefited. "Prior to the third death, SRPT's internal stress tests suggested the DMD franchise could 'floor' at $1.4B annually into 2027, including $500M+ for Elevidys in ambulatory," Tsai wrote in a note to clients Sunday. "For Elevidys, one can point to how the deaths have occurred only in older patients." "More cost reductions is possible too," Tsai noted of how Sarepta could end up handling the hit. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
Yahoo
12 minutes ago
- Yahoo
The Artificial Intelligence Underwriting Company launches with $15M to help enterprises deploy AI with confidence
Insurance built the modern world. It will unlock AI's future progress. SAN FRANCISCO, July 23, 2025 /PRNewswire/ -- Superintelligence is within reach. In just five years, AI has advanced from preschool-level capabilities to systems that can reason and act with the skill of an undergraduate. Proof of concepts are emerging across industries—from finance and legal to healthcare, drug discovery, and frontier technologies—but enterprises hesitate to deploy AI agents that feel like black boxes. They don't know which tools they can trust or who will be accountable if something goes wrong. There's a fear that hallucinated responses or unsafe outputs could lead to customer harm, revenue loss, regulatory risk, or reputational fallout. Today, the Artificial Intelligence Underwriting Company (AIUC) launches to unlock the next wave of AI progress by building the confidence infrastructure for AI agents. The company also announces a $15 million seed round led by Nat Friedman at NFDG, with participation from Emergence, Terrain and others including Ben Mann, co-founder of Anthropic; and former chief information security officers at Google Cloud and MongoDB. Enterprises are walking a tightrope. On the one hand, they face an "adopt or die" moment as their industries are transforming overnight. On the other hand, when AI fails spectacularly, the consequences are steep and customer trust is breached. AIUC gives enterprises a way to adopt AI with confidence, before their competitors do it faster. This playbook is time-tested throughout American history. In the 18th century, Benjamin Franklin responded to the fires ravaging Philadelphia not with bans, but with the country's first mutual fire insurance company. In the 19th century, when electricity posed new threats, insurance companies built UL Labs to test and certify the new technology. In the 20th century, as cars shaped modern life, insurers created safety standards and crash tests. Each time, insurance has made bold progress possible, before regulators could catch up. To help enterprises deploy AI agents with confidence, AIUC is structured around three pillars: Standards. AIUC-1 is a security and risk framework built specifically for AI agents. Think of it as "SOC-2 for AI agents." The standard is designed to speed up enterprise adoption by addressing the technical, legal and operational safeguards that matter most to enterprise buyers. AIUC-1 builds on existing trusted frameworks, including the NIST's AI Risk Management Framework, the EU AI Act, and MITRE's ATLAS–and goes further by defining clear, auditable requirements. That means AI companies can be certified against it, giving enterprises a concrete signal of safety and trust. Audits. For AI agents, independent audits give enterprises the confidence to adopt these systems. AIUC conducts rigorous testing of AI agents against the AIUC-1 standard. These audits identify vulnerabilities, quantify risk, and give enterprises a clear view of the AI systems they are evaluating, before actually deploying. This process is structured to be objective, repeatable, and aligned with enterprise-grade expectations for safety and trust. Insurance. AIUC offers liability coverage for AI vendors and their customers in case an agent fails. The cost and availability of insurance are tied directly to audit results: safer systems are offered better terms. This aligns incentives for builders, buyers and insurers, making it easier for enterprises to adopt new technology with confidence. "This is the path forward for faster, more secure AI adoption", said Rune Kvist, co-founder and CEO. "Every major technological leap in history, from electricity and automobiles to flight and the internet, was unlocked by private market insurance. That is what we're building for this major leap. Confidence infrastructure that rewards responsibility, unlocks speed, and enables enterprises to make informed decisions." The founding team brings deep experience across AI safety and institutional risk. Rune Kvist (co-founder, CEO) was the first product and go-to-market hire at Anthropic. He also sits on the board of the Center for AI Safety. Brandon Wang (co-founder, CTO) is a Thiel Fellow who previously founded a consumer underwriting business. Rajiv Dattani (co-founder) is a former McKinsey partner who led work in the global insurance sector, and was COO of METR, a research non-profit that evaluated OpenAI and Anthropic's models before deployment. For more information, visit About Artificial Intelligence Underwriting CompanyThe Artificial Intelligence Underwriting Company (AIUC) helps enterprises answer one critical question: Can we trust this AI agent? Founded by a team of leaders from Anthropic, McKinsey, Center for AI Safety, and METR, AIUC combines audits, standards, and insurance to enable confident AI adoption to unlock progress. View original content: SOURCE Artificial Intelligence Underwriting Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Bessent says Fed forecasts 'politically biased'
WASHINGTON (Reuters) -U.S. Treasury Secretary Scott Bessent on Wednesday suggested without evidence that the Federal Reserve's widely followed economic forecasts are motivated by politics, as the Trump administration steps up pressure on the U.S. central bank to cut interest rates. "The Fed publishes something called a summary of economic projections, and it's pretty politically biased," Bessent said, summarizing the projections as forecasts for one to two quarter-point interest-rate cuts this year. President Donald Trump has demanded the Fed deliver an immediate 300 basis-point rate cut. The Fed publishes interest-rate forecasts from each of its 19 policymakers each quarter and does not identify which policymaker made which forecast. In June, eight projected two quarter-point interest-rate cuts this year, seven projected none, two saw one interest rate cut and two saw three. Two of the Fed Board's Trump appointees - Governor Christopher Waller and Fed Vice Chair for Supervision Michelle Bowman -- have each articulated economic reasons for supporting a rate cut this month. Fed Chair Jerome Powell, also a Trump appointee, has not signaled such support. Fed policymakers universally reject the idea that politics have any role in their monetary policy decisions, and say that to suggest they do undermines the central bank's credibility and its ability to do its job fighting inflation and promoting maximum employment. Sign in to access your portfolio
